Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of November 16, 2025 [1]. Core Insights - The pharmaceutical industry is experiencing varied price cycles for raw materials, with certain products like Amoxicillin and 6-APA benefiting from stable supply and increased demand, leading to a prosperous period from 2023 to 2024. Vitamin E is also expected to see a high demand year in 2024 due to an incident at BASF [2]. - The high-value consumables market is showing growth in segments such as vascular intervention and neurosurgery, while orthopedic implants are facing a decline overall. However, specific areas like spinal and joint implants are growing, indicating a recovery in the industry post-tender clearing [3]. - The flu positivity rate has surged, leading to increased attention on flu medications and testing, with new flu drugs receiving approval from the National Medical Products Administration [4]. - The pace of innovation and overseas expansion in the pharmaceutical sector is recovering, with a significant increase in licensing deals and total transaction amounts in 2025 compared to previous years [5]. - The competitive landscape in the weight loss market is intensifying, with major companies like Novo Nordisk and Pfizer engaging in acquisition battles, highlighting the market's attractiveness [6]. - The research services and Contract Research Organization (CRO) sectors are leading the recovery in the pharmaceutical industry, with significant profit growth reported in these areas [8]. Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical sector has outperformed the CSI 300 index recently, with a weekly increase of 3.29% [22]. 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 39.36, above the five-year historical average of 31.22 [48]. 3. Recent Research Achievements - The report highlights various research achievements, including the growth of innovative drugs and the positive outlook for the blood products industry [50]. 4. Recent Industry Policies and News - Recent policies from the National Medical Insurance Administration focus on intelligent auditing and regulation of excessive prescriptions, aiming to safeguard fund security and patient rights [52].

Group 1 - The core view of the report indicates that the innovative drug market is expected to drive continuous valuation recovery in the pharmaceutical sector, supported by improving fundamentals and overseas expansion catalysts [2][7][10] - The pharmaceutical sector's overall performance shows a slight revenue growth of 0.2% year-on-year in Q3 2025, while net profit attributable to the parent company decreased by 12.87% [4][3] - The report highlights that the revenue of domestic biotech innovative drug companies reached 52.13 billion yuan in H1 2025, marking a 14% year-on-year increase, indicating that commercialization is entering a rapid growth phase [21][24] Group 2 - The report notes that the total overseas licensing business development (BD) transaction amount in the innovative drug sector exceeded 100 billion USD in 2025, with expectations for continued growth in 2026 [27][30][33] - The report emphasizes that the innovative drug sector's valuation remains at a historically low level, with the median PE ratio for the pharmaceutical sector at 34.21 times, suggesting potential for further recovery [10][57] - Institutional enthusiasm for the biotech innovative drug sector is reflected in the increasing proportion of holdings, with the weight of all funds in the biotech sector rising to 2.66% in Q3 2025 [11][35][38] Group 3 - The report identifies key companies to watch, including Sanofi Biopharma, which has licensed a PD-1/VEGF dual antibody to Pfizer, indicating high certainty for future overseas sales growth [63] - The report also highlights the potential of Union Pharmaceuticals' UBT251, which has shown promising results in weight loss and is licensed to Novo Nordisk [63] - The report suggests that Kolon Biotech's TROP2 ADC, licensed to Merck, has demonstrated excellent data and is expected to have significant market potential [63]

Group 1 - The innovative drug sector is expected to perform well in 2025, driven by overseas expansion expectations and rapid sales growth. The sector has shown significant excess returns in the first three quarters of 2025, primarily due to continuous business development (BD) overseas, excellent clinical data, and policy support. The sector is in a rapid sales growth phase, with several major products approved and included in medical insurance, leading to a surge in domestic sales and overseas revenue growth [5][6][56] - Chinese innovative drugs are demonstrating global competitiveness, with a significant increase in the number and value of outbound licensing deals. The proportion of Chinese assets in multinational corporation (MNC) drug transactions rose from approximately 5% in 2020-2021 to over 15% in the first three quarters of 2025. The total transaction amount for Chinese assets reached $47.6 billion, accounting for about 25% of MNC transactions [5][6][64] - After BD, attention should be focused on global clinical advancements and key data readouts. Since 2023, more Chinese assets have entered global registration clinical phases, with several expected to report phase III clinical data starting in 2026, potentially giving them a competitive edge through superior clinical data [5][6][64] Group 2 - The innovative drug sector's revenue has rapidly increased, with a reported revenue of 48.83 billion yuan (+22.1%) and a net profit of -460 million yuan (+71.4%) in the first three quarters of 2025. The third quarter alone saw revenues of 19.21 billion yuan (+51.0%) and a net profit of 1.11 billion yuan (+147.1%) [5][56] - The rapid growth in commercial sales of innovative drug products is attributed to the continued release of major products, medical insurance coverage, and the expansion of new indications. Additionally, overseas sales have become a key driver of revenue growth, alongside milestone payments from licensing agreements [5][56] - The investment recommendation highlights companies with differentiated innovation capabilities, suggesting a focus on Keren Biotechnology, Kangfang Biologics, Sanofi Pharmaceutical, Yingen Biotech, and Zai Lab [5][6]

- The report constructs an ETF hotspot trend strategy based on the highest and lowest price trends of ETFs, selecting those with both highest and lowest prices in an upward trend. Further, it constructs a support-resistance factor based on the relative steepness of the regression coefficients of the highest and lowest prices over the past 20 days, and selects the top 10 ETFs with the highest turnover rate in the past 5 days/20 days to construct a risk parity portfolio[27][30] - The report tracks the performance of various style factors, noting that the value factor recorded a positive return of 2.36%, the leverage factor recorded a positive return of 1.08%, and the volatility factor slightly rebounded with a return of 0.19%[41][42] - The report evaluates the performance of different alpha factors, highlighting that the quick ratio factor had the best performance with a weekly excess return of 1.32%, followed by the debt-asset ratio factor with a weekly excess return of 1.21%, and the earnings variability over 5 years factor with a weekly excess return of 1.04%[44][46][47] - The ETF hotspot trend strategy recorded a cumulative excess return over the CSI 300 index since the beginning of the year[28][29] - The value factor achieved a weekly return of 2.36%, the leverage factor achieved a weekly return of 1.08%, and the volatility factor achieved a weekly return of 0.19%[41][42] - The quick ratio factor achieved a weekly excess return of 1.32%, the debt-asset ratio factor achieved a weekly excess return of 1.21%, and the earnings variability over 5 years factor achieved a weekly excess return of 1.04%[44][46][47]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes short-term attention to the flu market while advocating a long-term focus on innovation [2][4] - The pharmaceutical sector has shown strong performance recently, driven by factors such as the flu epidemic and upcoming national medical insurance negotiations [4][12] - The report suggests focusing on specific segments like flu vaccines, flu medications, respiratory testing, and high-end medical devices for long-term investment [4][12] Summary by Sections 1. Industry Weekly Viewpoints - The pharmaceutical and biotechnology sector's weekly return was 3.29%, outperforming the CSI 300 by 4.37%, ranking 5th among 31 sub-industry indices [4][12] - The flu epidemic is currently on the rise, with ILI percentages in southern and northern regions exceeding previous years [4][12] - Upcoming medical insurance negotiations involve 120 companies, with results expected in early December [4][12] 2. Market Performance and Valuation - The pharmaceutical sector's recent one-month return was 1.16%, ranking 20th among sub-industry indices [15][24] - The current PE (TTM) for the pharmaceutical industry is 30.84, above the historical average of 28.97 [19][21] 3. Focus on Specific Stocks - Recommended stocks for flu vaccines include Huashan Vaccine and Jindike [4][12] - For flu medications, companies like Zhongsheng Pharmaceutical and Jichuan Pharmaceutical are highlighted [4][12] - In high-end medical devices, companies such as Mindray Medical and Yuyue Medical are suggested for investment [4][12] 4. Industry and Company Dynamics - Recent policy developments include discussions on medical insurance payment policies and adjustments to payment grouping schemes [4][12] - Notable company performances include BeiGene's Q3 revenue of $1.4 billion, a 41% increase year-on-year, and Innovent Biologics' revenue growth of 59.8% [4][12]

Market Review - Global stock indices showed divergence this week, with European, Brazilian, and Indian indices rising, while Chinese and American tech stocks declined. The Shanghai Composite Index continued its narrow fluctuation, with major broad indices generally adjusting. The average daily trading volume in the A-share market remained around 2 trillion yuan, indicating a focus on existing stock games. Growth leaders fell while small-cap stocks rose, with the micro-cap index increasing by 4.11% [1][2] - In terms of sector performance, the TMT, machinery, and military sectors saw the largest declines, while precious metals and copper prices rose, and domestic double焦 prices weakened [1][2] Market Outlook - The core theme for November remains "small-cap stocks + thematic investment." The recent pullback in Chinese and American tech stocks is attributed to tight overseas liquidity and concerns over AI bubbles. Future attention will be on U.S. economic data and changes in December rate cut expectations. The current A-share market is primarily focused on existing stock games, with financing and southbound trading showing a "high-low cut" trend. The performance benchmark for public funds is expected to curb issues like style drift and short-term ranking chasing, potentially weakening extreme institutional clustering [2][3] Fundamental Analysis - The domestic economy is expected to achieve a growth rate of around 5% for the year, despite a weakening trend in both supply and demand in October. Industrial added value growth was 6.1%, continuing to decline. Investment in narrow infrastructure turned negative, and real estate development investment and sales areas also saw significant declines. Retail sales growth was only 2.9%, marking five consecutive months of decline, particularly in major consumer goods. However, corporate earnings are stabilizing, and with PPI growth expected to turn positive next year, the potential for profit improvement in certain sectors is anticipated [3][4] Macro Policy - Future policy observations will focus on the December Political Bureau meeting and the Central Economic Work Conference. The central bank has reiterated "cross-cycle adjustment," signaling a balance between long-term goals and supportive monetary policy. The third-quarter monetary policy report indicates that the national economy is progressing steadily, with a solid foundation for achieving annual targets. The central bank's focus is shifting towards supporting policies that consider long-term objectives [4] Funding Dynamics - Since November, market style has shifted, with tech leaders retreating and small-cap stocks outperforming. This is due to concerns over the AI bubble affecting tech sentiment in A-shares. Financing transactions in sectors like semiconductors and communication equipment have seen net selling since November. Southbound funds have favored banks and oil sectors, leading to a phase where value stocks outperform tech stocks. Recent guidelines from the fund industry association aim to curb style drift and extreme clustering among funds, prompting some capital to migrate towards underweight sectors [5][6] Industry Configuration - Focus on "14th Five-Year Plan" related thematic investments, such as energy storage, batteries, domestic substitution, and new materials. Attention should also be given to sectors benefiting from "anti-involution" trends, such as chemicals, and the guidance signals from Hong Kong's innovative pharmaceuticals to A-shares [5]

Core Viewpoint - The current A-share market is in the high position of "Bull Market 1.0," with insufficient long-term cost-effectiveness in the technology sector and logical breaks in the cyclical market. Conditions for the initiation of Bull Market 2.0 are not yet complete [1] Group 1: Market Conditions - The A-share AI industry chain is in a state of "long-term low cost-effectiveness" similar to previous years in various sectors, indicating a high-level consolidation phase followed by an adjustment phase [2] - The high-level consolidation phase typically lasts at a quarterly level, and adjustments are triggered by mid-level disturbances in the industry trend, but this does not signify the end of the industry trend [2] Group 2: Cyclical Market Analysis - The recent cyclical market is characterized by short-term price increases and expectations of PPI turning positive by mid-2026, but there is significant divergence regarding the pace of PPI improvement [3] - The cyclical market is approaching a differentiation phase as cost-effectiveness decreases, and the sustainability of price increases becomes more critical [3] Group 3: Future Challenges - By spring 2026, the A-share market may face three major challenges: the technology sector's long-term low cost-effectiveness, a critical verification period for demand, and immature conditions for the transition to Bull Market 2.0 [4][5] - The market is expected to experience a two-stage bull market, with the first stage being the structural bull market in 2025 and a potential peak in spring 2026 [4][6] Group 4: Investment Opportunities - In the current high-level consolidation phase, the focus should be on Alpha opportunities in both cyclical and technology sectors, with an emphasis on sectors with favorable supply-demand dynamics and high dividend yields [7] - Short-term opportunities in technology growth are expected to arise from small rebounds, particularly in sectors with new catalysts or significant industry space, such as energy storage and innovative pharmaceuticals [7]

Group 1: Hong Kong Consumer Services Investment Strategy - The report emphasizes the importance of capturing certainty and focusing on marginal improvements in the Hong Kong consumer services sector for 2026 [2][8] - Macau gaming revenue shows resilience, with October gross gaming revenue increasing by 16% year-on-year, reaching the highest monthly record post-pandemic, driven by relaxed visa policies and events like concerts [2][8] - The report highlights the growth in VIP gaming revenue, which increased by 29% year-on-year, recovering to 54% of 2019 levels, while mass gaming revenue grew by 7% year-on-year, up 15% compared to 2019 [2][8] - The current EV/EBITDA valuation for the industry is at a low of 9 times, indicating potential for investment [2][8] - Recommended stocks include Galaxy Entertainment, MGM China, and Sands China [2][8] Group 2: Online Travel Sector - Online travel companies are experiencing revenue growth that outpaces the overall travel market, benefiting from increased online penetration and a focus on leisure travel rather than business travel [2][8] - Ctrip and Tongcheng Travel have not been adversely affected by new competitors, with improved marketing efficiency and higher growth rates in outbound and pure overseas travel segments [2][8] Group 3: Restaurant Sector - The restaurant sector faces fundamental pressures but continues to trend towards increased chain penetration, with significant elasticity expected if consumer sentiment improves [3][9] - The report recommends focusing on marginal changes in companies, highlighting ready-to-drink tea brands like Gu Ming and Mi Xue, as well as franchise models in lower-tier markets like Guo Quan [3][9] - Notable companies with strong shareholder returns include Yum China, which achieved record net openings for KFC and Pizza Hut in the third quarter [3][9] Group 4: Higher Education Sector - The report discusses the maturation of conditions for profit-oriented classification management in higher education, with expectations for a turnaround in the fortunes of higher education companies [4][13] - Recent policy developments in Guangdong province regarding private higher education classification management are anticipated to be followed by other provinces, enhancing the operational asset rights of listed private higher education companies [4][14] - The report predicts that after five years of quality improvement investments, the operational efficiency of higher education companies is expected to gradually recover, with a focus on quality enhancement as a regulatory goal [5][15] Group 5: Dividend Returns in Higher Education - The report anticipates a resumption of expansion for higher education companies once quality standards are met, leading to revenue growth and valuation increases [6][16] - With a current payout ratio of 30% and low valuation multiples, some higher education companies are expected to offer dividend yields exceeding 9%, providing a good margin of safety [6][16] - Recommended stocks include Yuhua Education, Zhongjiao Holdings, New Higher Education Group, and others [6][16] Group 6: Investment Analysis in Higher Education - The report suggests focusing on Hong Kong higher education companies, as the potential for profit-oriented classification is expected to revive expansion dynamics [20][31] - The report also highlights the positive performance of autumn enrollment data for K12 education companies, indicating strong brand appeal among students [20][31] - Recommendations include New Oriental, TAL Education, and others, with a particular emphasis on vocational education companies like China Oriental Education [20][31]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [7]. Core Insights - The report highlights that the pharmaceutical index increased by 3.29% during the week of November 10-14, 2025, indicating a positive market trend for innovative drugs and flu-related products [11][12]. - The report emphasizes the ongoing investment phase of major products in the pharmaceutical sector, particularly focusing on the BD (Business Development) second act for companies like Sanofi and their collaboration with Pfizer on SSGJ-707 [20][28]. - The report projects a bullish outlook for innovative drugs over the next 5-10 years, suggesting that a new wave of innovation and a bull market for innovative drugs is just beginning, with a focus on "disruption" rather than mere revaluation [14][12]. Summary by Sections 1. Recent Performance - The pharmaceutical sector showed resilience with a 3.29% increase in the index, while innovative drugs and flu treatments performed particularly well [11][12]. - The market is experiencing a rotation between high and low styles, benefiting both consumer and pharmaceutical sectors, especially innovative drugs [12][13]. 2. Investment Strategies - The report outlines specific investment strategies focusing on innovative drugs, including major overseas pharmaceutical companies and small to mid-cap technology revolutions [15][16]. - Key companies to watch include Innovent Biologics, Sanofi, and others in the innovative drug space, as well as those involved in new technologies like brain-computer interfaces and AI in healthcare [15][16]. 3. Future Outlook - The report anticipates continued optimism in the pharmaceutical sector, particularly around innovative drugs, with a focus on overseas major drugs and small-cap technology revolutions [14][15]. - It suggests that the investment landscape will evolve with a focus on leading companies that exhibit characteristics of leadership, disruption, and seriousness in their operations [14]. 4. Clinical Development Highlights - Pfizer's global clinical development plan for SSGJ-707 was disclosed, marking a significant milestone for Sanofi, with a $1.25 billion upfront payment for the collaboration [17][20]. - The report notes that the clinical trial phase for SSGJ-707 is just beginning, which is expected to catalyze further stock price increases for Sanofi [28][20]. 5. Sector Performance Comparison - The report compares the performance of the innovative drug index against the broader pharmaceutical index and the CSI 300 index, noting that the innovative drug index has outperformed both [31][32]. - The innovative drug index has increased by 30.65% since the beginning of 2025, indicating strong market interest and performance [32].

中新网深圳11月16日电 (记者索有为)正在举行的第二十七届中国国际高新技术成果交易会(简称"高交 会")上，高交会院士论坛——深圳创新药发展论坛暨重大项目签约活动举办，汇聚多位海内外院士、产 业领袖及创投精英等家热议生物医药创新浪潮。 此次论坛以"AI赋能向新而行"为主题，由深圳理工大学主办。深圳理工大学党委书记朱迪俭表示，作为 一所新型研究型大学，深圳理工大学正打通从基础研究到产业转化的全链条，也让拔尖创新人才加速成 长，该校将持续以科学家精神与特区精神为引领，在学科交叉中突破创新，在产教融合中赋能产业，为 大湾区国际科技创新中心建设与人类健康事业贡献坚实力量。 深圳市发展和改革委员会党组书记、主任郭子平表示，深圳持续推动生物医药产业高质量发展，不仅成 立市级药械产业办公室、出台系列支持政策，还建设了深圳医学科学院，布局多个国家级平台，设立超 百亿元产业基金，发力AI药物研发等新赛道。 论坛上，深圳理工大学围绕科研协作、人才培养等方面与深圳层次智慧生物、宁波酶赛生物、南京汉卫 公共卫生研究院、内蒙古自治区第四医院、深圳市百盈慈善基金会等企业、医疗机构、基金会完成8个 重大项目签约，以城校共融、开放办学等举 ...